Revance Therapeutics Inc (NASDAQ:RVNC)‘s stock had its “buy” rating reissued by Aegis in a report released on Friday. They presently have a $36.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $28.00. Aegis’ target price would indicate a potential upside of 86.05% from the stock’s current price.
Separately, Zacks Investment Research raised Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $35.17.
Revance Therapeutics (NASDAQ:RVNC) traded up 6.46% during trading on Friday, reaching $20.60. 396,950 shares of the company’s stock were exchanged. The stock’s market cap is $623.62 million. Revance Therapeutics has a 12 month low of $12.35 and a 12 month high of $24.30. The firm has a 50 day moving average of $20.89 and a 200-day moving average of $19.69.
Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by $0.10. Revance Therapeutics had a negative return on equity of 37.31% and a negative net margin of 28,187.33%. The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.07 million. During the same period in the prior year, the company posted ($0.71) earnings per share. The company’s revenue was up .0% on a year-over-year basis. On average, equities research analysts anticipate that Revance Therapeutics will post ($3.68) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Mideast Time and is the sole property of of Mideast Time. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.mideasttime.com/aegis-reaffirms-buy-rating-for-revance-therapeutics-inc-rvnc/1708344.html.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. increased its position in Revance Therapeutics by 34.7% in the first quarter. Goldman Sachs Group Inc. now owns 548,650 shares of the biopharmaceutical company’s stock worth $11,412,000 after buying an additional 141,400 shares in the last quarter. Bank of America Corp DE increased its position in Revance Therapeutics by 29.5% in the first quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,651 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in Revance Therapeutics by 4.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 92,490 shares of the biopharmaceutical company’s stock worth $1,924,000 after buying an additional 3,933 shares in the last quarter. Geode Capital Management LLC increased its position in Revance Therapeutics by 16.4% in the first quarter. Geode Capital Management LLC now owns 178,435 shares of the biopharmaceutical company’s stock worth $3,711,000 after buying an additional 25,075 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Revance Therapeutics by 5.1% in the first quarter. Vanguard Group Inc. now owns 868,118 shares of the biopharmaceutical company’s stock worth $18,056,000 after buying an additional 42,466 shares in the last quarter.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.